Business Context and Reporting Period
Company: Intrexon Corporation (Note: Request metadata referenced "PRECIGEN, INC." but the filing is for Intrexon Corporation).
Filing Type: Form 8-K (Current Report)
Reporting Date: April 2, 2015 (Earliest event reported: March 27, 2015)
Event: Entry into a Material Definitive Agreement (Ares Trading License and Collaboration Agreement) and an amendment to an existing agreement with ZIOPHARM Oncology, Inc.
Key Financial Metrics and Transaction Terms
- Upfront Payment: Ares Trading S.A. (a Merck KGaA affiliate) agreed to pay Intrexon an upfront fee of $115.0 million.
- Revenue Sharing: Intrexon is obligated to pay 50% of the upfront fee, all milestones, and all royalties received under the agreement to ZIOPHARM Oncology, Inc.
- Royalties: Ares Trading will pay Intrexon royalties ranging from lower-single digits to lower-double digits of net sales, subject to adjustment and potential increases via option exercise.
- Milestone Payments: Potential development and commercial milestone payments are capped at $413 million per Product (up to $826 million for the first two Products). Intrexon must remit 50% of these to ZIOPHARM.
- Stock Purchase Commitment: Intrexon's aggregate commitment to purchase ZIOPHARM common stock was reduced from $50.0 million to $43.0 million. Intrexon has fully satisfied this commitment ($43.5 million purchased).
Material Changes and Strategic Developments
The filing details a strategic shift in Intrexon's oncology portfolio through a worldwide collaboration with Ares Trading for the development and commercialization of Chimeric Antigen Receptor (CAR) T-Cell Products for cancer.
- Exclusivity: Intrexon and ZIOPHARM are restricted from developing or commercializing CAR T-Cell products in the defined field outside of this agreement, subject to specific "Out-of-Scope" exceptions.
- Roles: Intrexon is responsible for R&D and manufacturing for Phase 1 clinical trials. Ares Trading assumes responsibility for manufacturing post-Phase 1 and commercialization.
- Amendment to ZIOPHARM Agreement: The Second Amendment to the Exclusive Channel Partner Agreement (ECP Amendment) formally includes the CAR T-Cell products under the Intrexon/ZIOPHARM collaboration framework.
Outlook, Risks, and Contingencies
- Option Mechanism: Ares Trading holds an option to include "Out-of-Scope Targets" in the agreement by paying a cash fee and increased royalties. If not exercised, Intrexon may independently exploit these targets but must pay Ares Trading a lower double-digit percentage of consideration received (capped) and a mid-single-digit percentage credit thereafter.
- Termination Rights: Ares Trading may terminate the agreement voluntarily with 90 days' notice on a product-by-product or country-by-country basis. Upon termination, Ares Trading may continue developing products where Phase 3 trials have started or are being commercialized.
- Change in Control: Exclusivity obligations may be waived if a party is acquired, provided the competitive program does not use the acquired party's IP or personnel. If Intrexon or ZIOPHARM acquires a competitive program, they must divest it within 12 months or include it as an Out-of-Scope Product.
- Financial Statements: This 8-K filing does not provide updated revenue, profit, cash flow, or debt metrics for Intrexon Corporation. It focuses solely on the terms of the new agreement.
Investor Verification Checklist
- Verify the impact of the $115.0 million upfront payment on Intrexon's immediate cash position and tax implications.
- Confirm the specific terms of the "Out-of-Scope" option and the financial thresholds required for Ares Trading to exercise it.
- Review the detailed milestone definitions in Exhibit 10.1 to assess the likelihood of achieving the $413 million per product cap.
- Monitor the status of the Phase 1 clinical trials for which Intrexon is responsible, as this is the hand-off point to Ares Trading.
- Check subsequent filings for any changes to the $43.0 million stock purchase commitment or additional equity transactions with ZIOPHARM.